Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2019

Revenue From Contract With Customer [Abstract]

Disaggregated Revenues by Timing of Transfer of Goods or Services

The following tables present our revenues, disaggregated by timing of transfer of goods or services for the three and six months ended June 30, 2019 and 2018 (in thousands):

	Three Months Ended June 30, 2019						Six Months Ended June 30, 2019
	Product Revenue, net		Collaboration and License Revenue		Total		Product Revenue, net		Collaboration and License Revenue		Total
Timing of revenue recognition:
Transferred at a point in time	$	27,164	$	—	$	27,164	$	47,526	$	—	$	47,526
Transferred over time		—		1,260		1,260		—		3,067		3,067
Total	$	27,164	$	1,260	$	28,424	$	47,526	$	3,067	$	50,593

	Three Months Ended June 30, 2018						Six Months Ended June 30, 2018
	Product Revenue, net		Collaboration and License Revenue		Total		Product Revenue, net		Collaboration and License Revenue		Total
Timing of revenue recognition:
Transferred at a point in time	$	2,265	$	—	$	2,265	$	2,871	$	—	$	2,871
Transferred over time		—		1,746		1,746		—		7,784		7,784
Total	$	2,265	$	1,746	$	4,011	$	2,871	$	7,784	$	10,655

Schedule of Changes in Contract Assets and Liabilities

The following table presents changes in our contract assets and liabilities for the six months ended June 30, 2019 (in thousands):

	Balance at Beginning of Period		Addition		Deduction			Balance at End of Period
Contract assets:
Unbilled - collaboration and license revenue	$	9,880	$	2,452	$	(7,537	)	$	4,795
Total contract assets	$	9,880	$	2,452	$	(7,537	)	$	4,795
Contract liabilities:
Deferred revenue	$	6,335	$	1,112	$	(1,765	)	$	5,682
Total contract liabilities	$	6,335	$	1,112	$	(1,765	)	$	5,682

Significant changes in the contract liabilities balances during the period are as follows (in thousands):

	Three Months Ended as of June 30, 2019		Six Months Ended as of June 30, 2019
Revenue recognized according to the current period performance that was included in the contract liability at the beginning of the period	$	442	$	615

Estimated Revenue Expected to be Recognized in Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of June 30, 2019 (in thousands):

Collaborator	Transaction Price Allocated to the Remaining Performance Obligation as of June 30, 2019		Expected Year By Which Revenue Recognition Will Be Completed		Percentage of Revenue Recognized
BMS and Pfizer - 2016 agreement	$	856		2021		93	%
Daiichi Sankyo - 2014 agreement		942		2020		97	%
Daiichi Sankyo - 2016 agreement		3,120		2023		80	%
Bayer - 2016 agreement		2,487		2023		84	%
Total	$	7,405